1. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices

   • Andrew T. Kuykendall

   Review Article Open access 21 March 2023 Pages: 985 - 993

   

2. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments

   • Xiaolei Wei
   • Yongqiang Wei

   Review Article Open access 22 March 2023 Pages: 995 - 1009

3. Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs

   • Zhixin Sheng
   • Dianfang Li
   • Lida Wang

   Review Article 22 March 2023 Pages: 1011 - 1017

   

4. Estimated glomerular filtration rate in Brazilian adults with sickle cell disease: results from the REDS-III multicenter cohort study

   • André Rolim Belisário
   • Ana Cristina Simões e Silva
   • for the Recipient Epidemiology and Donor Evaluation Study (REDS-III) International Component Brazil

   Original Article 08 March 2023 Pages: 1019 - 1027

5. Targeted next-generation sequencing identifies eighteen novel mutations expanding the molecular and clinical spectrum of PKLR gene disorders in the Indian population

   • Rashmi Dongerdiye
   • Meghana Bokde
   • Prabhakar Kedar

   Original Article 09 March 2023 Pages: 1029 - 1036

   

6. The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival

   • Tamer Hellou
   • Omri Cohen
   • Jonathan Canaani

   Original Article 11 March 2023 Pages: 1037 - 1043

   

7. Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience

   • Sebastian E. Koschade
   • Jan A. Stratmann
   • Olivier Ballo

   Original Article Open access 22 March 2023 Pages: 1045 - 1052

   

8. Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States

   • Aditi Sharma
   • Jay Yang
   • Vijendra Singh

   Original Article 14 March 2023 Pages: 1053 - 1062

   

9. Loss of IRF8 inhibits the growth of acute myeloid leukemia cells

   • Haihui Zhuang
   • Fenglin Li
   • Ying Lu

   Original Article 23 March 2023 Pages: 1063 - 1072

   

10. Lycorine induces apoptosis of acute myeloid leukemia cells and inhibits triglyceride production via binding and targeting FABP5

    • Xinming Liang
    • Wenli Fu
    • Qifang Zhang

    Original Article 21 March 2023 Pages: 1073 - 1086

    

11. PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients

    • Luciana C Ferrari
    • María M Rivas
    • On behalf of the Grupo Argentino de Leucemias Agudas (GALA) and Grupo Argentino de Tratamiento de Leucemias Agudas (GATLA)

    Original Article 09 March 2023 Pages: 1087 - 1097

    

12. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study

    • Davide Lazzarotto
    • Ilaria Tanasi
    • Robin Foà

    Original Article 24 March 2023 Pages: 1099 - 1109

    

13. Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry

    • Ethan A. Burns
    • Cesar Gentille Sanchez
    • Sai Ravi Kiran Pingali

    Original Article 16 March 2023 Pages: 1111 - 1120

    

14. Clinical and histopathology characteristics of Castleman disease: a multicenter study of 51 Brazilian patients

    • Julia Mota Leite
    • Tomás Zecchini Barrese
    • Carlos Sérgio Chiattone

    Original Article 10 February 2023 Pages: 1121 - 1129

    

15. Pediatric chemotherapy versus allo-HSCT for adolescent and adult Philadelphia chromosome-negative ALL in first complete remission: a meta-analysis

    • Zengkai Pan
    • Luxiang Wang
    • Xiaoxia Hu

    Original Article 22 March 2023 Pages: 1131 - 1140

    

16. Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma

    • Kana Oiwa
    • Kei Fujita
    • Takahiro Yamauchi

    Original Article Open access 23 March 2023 Pages: 1141 - 1148

    

17. Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study

    • Ilseung Choi
    • Masaya Okada
    • Tomoki Ito

    Original Article 30 March 2023 Pages: 1149 - 1158

    

18. Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

    • J. Dufour
    • S. Choquet
    • C. Houillier

    Original Article 29 March 2023 Pages: 1159 - 1169

    

19. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation

    • Tianhong Xu
    • Yang Yang
    • Peng Liu

    Original Article 08 March 2023 Pages: 1171 - 1184

    

20. Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myeloma

    • Shuku Sato
    • Shun Tsunoda
    • Yotaro Tamai

    Original Article Open access 23 March 2023 Pages: 1185 - 1191

    

21. CMV infection is a risk factor for hemorrhagic cystitis after hematopoietic stem cell transplantation

    • Ling Zhang
    • Bijay Khadka
    • Jiajun Liu

    Original Article 08 February 2023 Pages: 1193 - 1201

    

22. Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients

    • Boris van der Zouwen
    • E. A. S. Koster
    • C. J. M. Halkes

    Original Article Open access 07 March 2023 Pages: 1203 - 1213

    

23. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database

    • Hidehiro Itonaga
    • Yasushi Miyazaki
    • Ken Ishiyama

    Original Article 15 March 2023 Pages: 1215 - 1227

    

24. Ferroptosis: a new target for iron overload-induced hemophilic arthropathy synovitis

    • Zhiwei Han
    • Liujie Zheng
    • Yunfeng Yao

    Original Article 23 March 2023 Pages: 1229 - 1237

    

25. Predictive scoring system for distinguishing Stenotrophomonas maltophilia bacteremia from Pseudomonas aeruginosa bacteremia in patients with hematological malignancies

    • Takashi Sakoh
    • Muneyoshi Kimura
    • Hideki Araoka

    Original Article 27 March 2023 Pages: 1239 - 1246

    

26. High TOX expression on CD8⁺ T cells in pure red cell aplasia

    • Haiyue Niu
    • Li Yan
    • Huaquan Wang

    Original Article 18 March 2023 Pages: 1247 - 1255

    

27. Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)

    • Massimo Breccia
    • Pier Paolo Olimpieri
    • Pierluigi Russo

    Letter to the Editor 13 March 2023 Pages: 1257 - 1259

    

28. Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients

    • Kai Ding
    • Zhaoyun Liu
    • Rong Fu

    Letter to the Editor Open access 13 March 2023 Pages: 1261 - 1263

    

29. Remarkable response to chidamide plus rituximab in an elderly patient with recurrent, chemotherapy-refractory diffuse larger B-cell lymphoma carrying CREBBP mutation

    • Dongdong Zhang
    • Yidi Han
    • Youhong Dong

    Letter to the Editor 29 March 2023 Pages: 1265 - 1268

    

30. Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis

    • Ralph Wäsch
    • Tim Strüssmann
    • Monika Engelhardt

    Letter to the Editor Open access 17 March 2023 Pages: 1269 - 1270

    

31. Sustained spontaneous remission in KMT2A-MLLT3 mutated myeloid sarcoma

    • Chris Armstrong
    • Wing-Yan Au
    • Nina Orfali

    Letter to the Editor 17 March 2023 Pages: 1271 - 1274

    

32. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia

    • Jie Chang
    • Yao-jia Shen
    • Hong-Hu Zhu

    Letter to the Editor 09 March 2023 Pages: 1275 - 1277

    

33. JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response

    • Luca Tosoni
    • Dora Fabbro
    • Mario Tiribelli

    Letter to the Editor 22 March 2023 Pages: 1279 - 1280

34. Double-hit follicular lymphoma diagnosed due to central nervous system symptoms

    • Chika Kawajiri-Manako
    • Tatsuzo Mishina
    • Masahiro Takeuchi

    Letter to the Editor 27 March 2023 Pages: 1281 - 1282

    

35. Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia

    • Yoshito Gando
    • Takeo Yasu

    Letter to the Editor 29 March 2023 Pages: 1283 - 1285